Biotech Valuations
Santhera's Single-Drug Bet on DMD: What Investors Need to Know About Vamorolone Pipeline Risk
ViaNews Editorial Team (Markets)•
#Duchenne Muscular Dystrophy
2 articles
Biotech Equities
REGENXBIO's RGX-202 Could Be a Major RGNX Catalyst: What Investors Need to Know About the 2027 DMD Launch
ViaNews Editorial Team (Markets)•